Back To: Home : Featured Technology : Assay Development

CLICK HERE FOR WHAT'S NEW IN:
 

Lab21, IntegraGen team up for colorectal CDx
April 2013
SHARING OPTIONS:

CAMBRIDGE, United Kingdom—A new agreement was established in late February between Lab21 Ltd. and IntegraGen for the development of a microRNA assay for colorectal cancer designed to improve patient outcomes. Per the agreement, Lab21 will develop a CE-marked assay to detect expression levels of hsa-mir-31-3p, a microRNA biomarker discovered and patented by IntegraGen and its partners that has shown to predict response to EGFR inhibitor therapy in KRAS wild-type patients with metastatic colorectal cancer. No financial details were released. Following assay development, Lab21 and IntegraGen will examine opportunities for manufacturing and commercialization partnerships for the biomarker.  
 
Bernard Courtieu, CEO of IntegraGen, said that, "on the basis of good clinical results and regulatory approval, we hope to have a CE-marked kit available based on Lab21's technology by early 2014."  
 

Back


PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.